357 related articles for article (PubMed ID: 14640983)
1. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2.
Pospísilová S; Brázda V; Kucharíková K; Luciani MG; Hupp TR; Skládal P; Palecek E; Vojtesek B
Biochem J; 2004 Mar; 378(Pt 3):939-47. PubMed ID: 14640983
[TBL] [Abstract][Full Text] [Related]
2. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A.
Luciani MG; Hutchins JR; Zheleva D; Hupp TR
J Mol Biol; 2000 Jul; 300(3):503-18. PubMed ID: 10884347
[TBL] [Abstract][Full Text] [Related]
3. A novel system to investigate the phosphorylation of the p53 tumor suppressor protein by the protein kinase CK2.
McKendrick L; Meek DW
Cell Mol Biol Res; 1994; 40(5-6):555-61. PubMed ID: 7735330
[TBL] [Abstract][Full Text] [Related]
4. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site.
Blaydes JP; Hupp TR
Oncogene; 1998 Aug; 17(8):1045-52. PubMed ID: 9747884
[TBL] [Abstract][Full Text] [Related]
5. Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential.
Mundt M; Hupp T; Fritsche M; Merkle C; Hansen S; Lane D; Groner B
Oncogene; 1997 Jul; 15(2):237-44. PubMed ID: 9244359
[TBL] [Abstract][Full Text] [Related]
6. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases.
Wang Y; Prives C
Nature; 1995 Jul; 376(6535):88-91. PubMed ID: 7596441
[TBL] [Abstract][Full Text] [Related]
7. Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vitro, but not in vivo, even after stimulation with the phorbol ester o-tetradecanoylphorbol 13-acetate.
Milne DM; McKendrick L; Jardine LJ; Deacon E; Lord JM; Meek DW
Oncogene; 1996 Jul; 13(1):205-11. PubMed ID: 8700548
[TBL] [Abstract][Full Text] [Related]
8. Cdk2 kinase phosphorylates serine 315 of human p53 in vitro.
Price BD; Hughes-Davies L; Park SJ
Oncogene; 1995 Jul; 11(1):73-80. PubMed ID: 7624134
[TBL] [Abstract][Full Text] [Related]
9. The carcinogen 2-acetylaminofluorene inhibits activation and nuclear accumulation of cyclin-dependent kinase 2 in growth-induced rat liver.
Lindeman B; Skarpen E; Oksvold MP; Huitfeldt HS
Mol Carcinog; 2000 Mar; 27(3):190-9. PubMed ID: 10708481
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator.
Bessa M; Saville MK; Watson RJ
Oncogene; 2001 Jun; 20(26):3376-86. PubMed ID: 11423988
[TBL] [Abstract][Full Text] [Related]
11. Specific DNA binding by p53 is independent of mutation at serine 389, the casein kinase II site.
Rolley N; Milner J
Oncogene; 1994 Oct; 9(10):3067-70. PubMed ID: 8084615
[TBL] [Abstract][Full Text] [Related]
12. Different mechanisms for inhibition of cell proliferation via cell cycle proteins in PC12 cells by nerve growth factor and staurosporine.
Gollapudi L; Neet KE
J Neurosci Res; 1997 Aug; 49(4):461-74. PubMed ID: 9285522
[TBL] [Abstract][Full Text] [Related]
13. CaMK-II inhibition reduces cyclin D1 levels and enhances the association of p27kip1 with Cdk2 to cause G1 arrest in NIH 3T3 cells.
Morris TA; DeLorenzo RJ; Tombes RM
Exp Cell Res; 1998 May; 240(2):218-27. PubMed ID: 9596994
[TBL] [Abstract][Full Text] [Related]
14. Mapping of the interaction sites of the growth suppressor protein p53 with the regulatory beta-subunit of protein kinase CK2.
Appel K; Wagner P; Boldyreff B; Issinger OG; Montenarh M
Oncogene; 1995 Nov; 11(10):1971-8. PubMed ID: 7478515
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the DNA binding of p53 by its interaction with protein kinase CK2.
Prowald A; Schuster N; Montenarh M
FEBS Lett; 1997 May; 408(1):99-104. PubMed ID: 9180277
[TBL] [Abstract][Full Text] [Related]
16. Signaling to p53: breaking the posttranslational modification code.
Appella E; Anderson CW
Pathol Biol (Paris); 2000 Apr; 48(3):227-45. PubMed ID: 10858956
[TBL] [Abstract][Full Text] [Related]
17. Characterization of protein kinase activities associated with p53-large-T immune complexes from SV40-transformed rat cells.
Müller E; Boldyreff B; Scheidtmann KH
Oncogene; 1993 Aug; 8(8):2193-205. PubMed ID: 8393163
[TBL] [Abstract][Full Text] [Related]
18. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
Rao S; Lowe M; Herliczek TW; Keyomarsi K
Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of p53/p21Cip1/Waf1 pathway contributes to polyploidy and apoptosis of E1A+cHa-ras transformed cells after gamma-irradiation.
Bulavin DV; Tararova ND; Aksenov ND; Pospelov VA; Pospelova TV
Oncogene; 1999 Oct; 18(41):5611-9. PubMed ID: 10523840
[TBL] [Abstract][Full Text] [Related]
20. Binding of RNA to p53 regulates its oligomerization and DNA-binding activity.
Yoshida Y; Izumi H; Torigoe T; Ishiguchi H; Yoshida T; Itoh H; Kohno K
Oncogene; 2004 May; 23(25):4371-9. PubMed ID: 15064727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
